India's ISDE 2026 Breakthrough: Robotic Surgery & Organ-Preserving Care That Costs a Fraction of the West

On April 10–11, 2026, Hyderabad, India became the center of the global esophageal cancer conversation. The International Society for Diseases of the Esophagus (ISDE) held its India Edition 2026 conference in association with the Basavatarakam Indo-American Cancer Hospital & Research Institute, coinciding with the institution's 25th anniversary. Over 150 oncologists from Canada, Singapore, Japan, Australia, and the USA descended on The Westin Hyderabad to share the latest advances in treating one of the world's most aggressive malignancies.

Esophageal cancer has long been a grim diagnosis. Historically, nearly nine in ten patients succumbed to the disease, and many went untreated due to a lack of trained specialists. But the ISDE 2026 conference painted a very different picture of where the field is heading.

Four themes dominated the sessions:

• Robotic esophagectomy — minimally invasive removal of the esophagus with greater precision and faster patient recovery
• Endoscopic Submucosal Dissection (ESD) — an organ-preserving technique that removes early-stage tumors through an endoscope, avoiding surgery altogether in select cases
• Advanced multimodal therapy — combining chemotherapy, radiotherapy, and immunotherapy in coordinated protocols to improve survival in locally advanced cases
• Translational research integration — bringing laboratory findings on tumor biology into targeted, personalized treatment plans

Perhaps the most striking figure shared at the conference: cancer treatment in the United States can cost up to 70 times more than in India, and around 25 times more than in Singapore. India is positioning itself not just as a low-cost destination, but as a clinical leader in esophageal cancer care, a message reinforced by a 500-bed expansion of Basavatarakam Cancer Hospital in Amaravati, scheduled to open in 2028.

China is, by any measure, an esophageal cancer heavyweight. The country records approximately 477,000 new cases and 375,000 deaths annually, representing about half of the global burden. Linzhou in Henan province has long been known as the "esophageal cancer capital" of the world, where dietary habits (including consumption of extremely hot beverages and nitrite-rich foods) have contributed to persistently high rates.

Chinese hospitals have responded with substantial investment in both volume and capability. Key centers include:

• Anyang Cancer Hospital (Henan) — one of the world's highest-volume esophageal cancer treatment centers, deeply embedded in the Linzhou screening ecosystem
• Tianjin Medical University Cancer Hospital — a national leader in surgical oncology and multimodal therapy protocols
• Peking Union Medical College Hospital (PUMCH, Beijing) — China's most prestigious referral center with advanced endoscopy and early cancer detection programs
• Fudan University Cancer Hospital (Shanghai) — strong research arm and clinical trial activity in upper GI cancers

On the technology front, Chinese major hospitals have widely adopted ESD for early esophageal neoplasia, and several tier-1 centers offer robotic-assisted esophagectomy using the Da Vinci system. Proton therapy centers in Shanghai and other cities have also expanded the toolkit for esophageal cancer treatment, particularly for patients where conventional radiotherapy carries high risk to adjacent organs like the heart and lungs.

The Chinese government's Cancer Prevention and Control Action Plan (2023–2030) has put early screening in high-risk regions front and center, with screening programs in Henan, Shanxi, and Hebei provinces already saving lives through detection of early-stage disease where organ-preserving treatments are most effective.

• Both countries offer top-tier care at a fraction of Western costs. Whether a patient chooses India or China, they're accessing outcomes that rival the US or Europe, at prices 10 to 70 times lower.
• The ISDE 2026 message is clear: organ preservation is the future. ESD and other endoscopic techniques can eliminate early-stage tumors without major surgery, preserving quality of life. Chinese screening programs in high-risk regions give it a head start in catching cancer early enough to use these techniques.
• China's scale is unmatched, but India's medical tourism brand is stronger internationally. India has aggressively marketed itself as a global health destination. China's inbound medical tourism, while growing rapidly (particularly in Hainan's Lecheng zone), is still finding its footing on the world stage.
• For international patients seeking esophageal cancer treatment, geographic convenience may tip the balance. China's proximity to Southeast Asia, East Asia, and Central Asia makes it the natural choice for regional patients. India's established medical tourism infrastructure and English-language environment make it the preferred choice for patients from the Middle East, Africa, and South Asia.
• The 500-bed Basavatarakam expansion (2028) signals a major long-term commitment. This mirrors China's own hospital expansion wave and suggests both countries will be competing harder for international patients in the coming years.

• Cancer Treatment Services in China — Overview of surgical, chemotherapy, radiotherapy, and emerging therapies available at partner hospitals
• Advanced Endoscopy in China — Learn about ESD, EUS, and other organ-preserving endoscopic procedures
• Latest Medical News from China — More coverage of breakthrough treatments and comparisons
• ISDE, International Society for Diseases of the Esophagus (external)